1. Home
  2. INGN vs HURA Comparison

INGN vs HURA Comparison

Compare INGN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inogen Inc

INGN

Inogen Inc

HOLD

Current Price

$6.69

Market Cap

177.1M

Sector

Health Care

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.17

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
INGN
HURA
Founded
2001
2009
Country
United States
United States
Employees
N/A
22
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.1M
160.5M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
INGN
HURA
Price
$6.69
$2.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$11.25
$9.50
AVG Volume (30 Days)
221.8K
731.4K
Earning Date
05-07-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
43.42
N/A
EPS
N/A
N/A
Revenue
$348,668,000.00
N/A
Revenue This Year
$8.03
N/A
Revenue Next Year
$7.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.86
N/A
52 Week Low
$5.34
$0.41
52 Week High
$9.13
$3.90

Technical Indicators

Market Signals
Indicator
INGN
HURA
Relative Strength Index (RSI) 53.70 44.01
Support Level $6.59 $2.10
Resistance Level $6.72 $2.20
Average True Range (ATR) 0.26 0.21
MACD -0.01 -0.02
Stochastic Oscillator 48.80 20.00

Price Performance

Historical Comparison
INGN
HURA

About INGN Inogen Inc

Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: